Company profile
ERASCA, INC.
NASDAQ:ERASBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CETUXIMAB | phase1_2 | — | 48 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04670679 | phase1 | completed | 2020-12-15 | 2026-02-01 | Erasca, Inc. | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
| NCT04959981 | phase1 | completed | 2021-09-02 | 2023-04-27 | Erasca, Inc. | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC |
| NCT05279859 | phase1_2 | withdrawn | 2022-03-15 | 2025-03-01 | Erasca, Inc. | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies |
| NCT06983743 | phase1 | recruiting | 2025-06-05 | 2028-05-01 | Erasca, Inc. | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors |
| NCT04866134 | phase1_2 | completed | 2021-05-07 | 2026-07-01 | Erasca, Inc. | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
FDA applications (0)
No records yet.